CUBA STANDARD — Putting it among the top vaccines in the world, COVID-19 candidate Abdala showed 92.28% efficacy in three doses during Phase-3 clinical testing, the Centro de Ingeniería Genética y Biotecnología (CIBG) announced.
Four days before the announcement, Vietnam’s Institute of Vaccines and Medical Biologicals (IVAC) said it may manufacture the vaccine in Vietnam. Other countries, such as Argentina, have expressed their intent to fund vaccine manufacturing in Cuba, to secure a steady supply. In contrast to similarly effective vaccines that require extra-cold freezer storage, Abdala can be stored at between 2 and 8 degrees centigrade.
On June 24, a first batch of Abdala arrived in Venezuela; the Venezuelan government said it will purchase 12 million doses.
Mexico also expressed interest in purchasing the vaccine.
Welcome to our site! Please consider acquiring a membership to access exclusive content. Click here to subscribe.
